The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Combining ibrutinib with CAR-T cells: a promising therapeutic strategy in CLL
In this video, Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses the promise of combining CAR-T cells with BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL). Dr Ruella highlights recent research in this space, and further comments on how combining ibrutinib with CAR-T cells can increase the anti-tumor effect of T-cells, resulting in a promising therapeutic strategy. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
